Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.

Abstract

To compare the effects of naftopidil and silodosin administration on the quality of life of patients with prostate cancer who underwent low-dose-rate brachytherapy. In total, 141 men diagnosed with localized prostate cancer who were treated with low-dose-rate brachytherapy were enrolled. Patients were randomized (1:1) to the naftopidil (75mg/day, n=63) or silodosin group (8mg/day, n=64). Naftopidil and silodosin were administered 1day after low-dose-rate brachytherapy, and were continued for at least 3months. Using the University of California at Los Angeles Prostate Cancer Index and Sexual Health Inventory for Men scores, the mean changes and rates of deterioration from baseline were compared. The deterioration rates in the quality of life of patients at 1 and 3months after low-dose-rate brachytherapy were evaluated based on the minimal important difference. The rates of deterioration from baseline to 1 and 3months after low-dose-rate brachytherapy were not significantly different between the two groups in terms of urinary function, urinary bother, bowel bother, sexual function or Sexual Health Inventory for Men scores. In contrast, there were significant differences in bowel function (naftopidil 1month, 52%; 3months, 52%; silodosin 1month, 28%; 3months, 34%; 1month, P<0.01; 3months, P=0.048) and sexual bother (naftopidil 3months, 11%; silodosin 3months, 29%; P=0.01). Naftopidil and silodosin provide different disease-specific quality of life outcomes in patients undergoing, especially in terms of bowel function and sexual bother. These findings can help in the selection of α-1 adrenoceptor antagonists after low-dose-rate brachytherapy.